Epigallocatechin gallate's protective effect against MMP7 in recessive dystrophic epidermolysis bullosa patients.
The analysis of phenotype-genotype correlations of patients suffering from recessive dystrophic epidermolysis bullosa (RDEB) evidenced intrafamilial and interfamilial phenotype variability occurring for the same mutation of COL7A1; this underscores the role of other genetics environmental factors in the expressivity of the disease. In this work, we checked whether matrilysin 1 (matrix metalloproteinase (MMP)7) could take part in the epidermal detachment in RDEB. Furthermore, we investigated epigallocatechin 3 gallate (EGCG) to determine whether it could inhibit matrilysin activities on collagen type VII and fibrillin 1 known to be associated with the dermo-epidermal junction. In this work, matrilysin 1 was detected in affected and unaffected skins of the three RDEB patients; furthermore, MMP7 was shown to degrade ex vivo on healthy normal skin collagen VII and fibrillin 1. Thus, we suspect that MMP7 could take an active part in the epidermal detachment occurring during RDEB. We evidenced that EGCG in in vitro as well as in ex vivo experiments was a good inhibitor of MMP7 and developed a good protection of collagen type VII and fibrillin 1 susceptible of being degraded by MMP7. We therefore propose that EGCG could be used beneficially in patients suffering from RDEB.
Changotade
Sylvie Igondjo-Tchen
SI
Faculté de Chirurgie Dentaire de Montrouge, Université Paris, Montrouge, France.
Assoumou
Antoine
A
Guéniche
Farida
F
Fioretti
Florence
F
Séguier
Sylvie
S
de Prost
Yves
Y
Bodemer
Christine
C
Godeau
Gaston
G
Senni
Karim
K
D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D015153:Blotting, Western; D002392:Catechin / Q000031:analogs & derivatives* / Q000494:pharmacology; D024143:Collagen Type VII / Q000378:metabolism; D004547:Elastic Tissue / Q000473:pathology; D016108:Epidermolysis Bullosa Dystrophica / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D000071838:Fibrillin-1; D000071837:Fibrillins; D005808:Genes, Recessive; D006801:Humans; D007158:Immunologic Techniques; D020783:Matrix Metalloproteinase 7 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D008840:Microfilament Proteins / Q000378:metabolism; D009924:Organ Culture Techniques; D011480:Protease Inhibitors / Q000494:pharmacology*; D012867:Skin / Q000201:enzymology / Q000473:pathology; D013194:Staining and Labeling; D013997:Time Factors; D014018:Tissue Distribution; D000097382:CD68 Molecule; D054392:Adipokines
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D002392:Catechin; D024143:Collagen Type VII; D000071838:Fibrillin-1; D000071837:Fibrillins; D020783:Matrix Metalloproteinase 7; D061965:Matrix Metalloproteinase Inhibitors; D008840:Microfilament Proteins; D011480:Protease Inhibitors; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C000605722:FBN1 protein, human; D054392:Adipokines; C045651:epigallocatechin gallate